Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : In preclinical models, MCLA-158 binding triggers EGFR degradation in LGR5+ CSCs and is designed to have two different mechanisms of action. The first entails blocking of growth and survival pathways in cancer initiating cells.
Brand Name : MCLA-158
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 07, 2021
LOOKING FOR A SUPPLIER?
Reset All
